CUA 2017: State of the Art Immunotherapy for Urologic Cancers. – UroToday
UroToday |
CUA 2017: State of the Art Immunotherapy for Urologic Cancers.
UroToday Since the interferon trials for metastatic kidney cancer in the 1990's, we have been waiting for subsequent immunotherapy breakthroughs. Over the past several years, we have certainly seen this with the targeting of immune checkpoints, first in … Now a cancer drug which avoids pain of chemotherapy? |
